Key result
Early GP IIb/IIIa inhibitors treat only 35% of eligible NSTE-ACS patients, paradoxically targeting lower-risk individuals.
Why the study?
Early glycoprotein IIb/IIIa inhibitor therapy remains underutilized in patients with NSTE ACS despite ACC/AHA guideline recommendations, and patient selection patterns for early use are unclear.
What are the patient selection patterns and associated treatment patterns for early glycoprotein IIb/IIIa inhibitor use in patients with non-ST-segment elevation acute coronary syndrome?
Population
65,424 patients with NSTE ACS presenting with ischemic chest pain <24 hours and positive cardiac markers or ischemic ECG changes from 443 U.S. hospitals
Comparison
Early (<24 hours) GP IIb/IIIa inhibitor use vs no early use
Design
Observational analysis using CRUSADE Quality Improvement Initiative database
Follow-up
In-hospital
Authors
Loading...
Underutilization and risk-mismatched GP IIb/IIIa use in NSTE ACS may signal care gaps; cohort data leave open optimal selection effects on outcomes.
Observational (n=65,424)
Yes
What are the patient selection patterns and associated treatment patterns for early glycoprotein IIb/IIIa inhibitor use in patients with non-ST-segment elevation acute coronary syndrome?
Early GP IIb/IIIa inhibitor therapy is underutilized in NSTE ACS, particularly among high-risk patients, despite being associated with better overall adherence to guidelines.
Hoekstra et al. (2005) conducted an observational in Non-ST-segment elevation acute coronary syndrome (NSTE ACS) (n=65,424). Early (<24 hours) glycoprotein (GP) IIb/IIIa inhibitor use vs. No early GP IIb/IIIa inhibitor use was evaluated on Patient selection patterns and adherence to other guidelines-recommended therapies. Early glycoprotein IIb/IIIa inhibitor therapy was utilized in only 35% of eligible NSTE ACS patients and was paradoxically directed toward lower-risk individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: